In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

Key Takeaways; Cannabis Sector Scotts Miracle-Gro will finally separate its cannabis arm, Hawthorne, into a stand-alone cannabis business High Tide narrowed losses in 2024 amid record revenue and ...

As the U.S. stock market navigates a week of fluctuating earnings reports and economic indicators, investors are keenly observing opportunities across various sectors. Penny stocks, often associated ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Both companies have zeroed in on a disorder that affects millions of people with the potential for huge financial success.

Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...

NEW YORK and BERLIN - atai Life Sciences (NASDAQ: ATAI), a biopharmaceutical company focused on mental health treatments with a current market capitalization of $243 million, announced positive ...

Life Sciences (ATAI) announced topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to ...

Somerset, NJ, Jan. 28, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the "Company”) (Nasdaq: CCLD, CCLDO, CCLDP), a leading provider of healthcare technology and generative AI solutions for medical ...

Part 2 of the study will investigate a single dose of BPL-003 in patients who are BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered ...